A breast cancer therapy that
blocks estrogen synthesis to activate cancer - killing genes sometimes loses its effectiveness because the cancer takes over
epigenetic mechanisms, including permanent DNA modifications in the patient's tumor, once again allowing tumor growth, according to an international team headed by the University of Pittsburgh Cancer Institute (UPCI).
Finally, a profound understanding of the molecular
mechanisms underlying reprogramming, and knowledge of the
epigenetic barriers that interfere or
block lineage conversion, will allow for developing even better reprogramming strategies; and, thus, also feed the aim of obtaining authentic neurons.